Progress in adjuvant therapy for colorectal cancer

Shunji Kohnoe, Yoshihiro Kakeji, Yoshihiko Maehara

Research output: Contribution to journalReview articlepeer-review


The progress and role of adjuvant therapy for resectable colorectal cancers are reviewed herein. 5-FU/leucovorin is considered the standard treatment in the postoperative adjuvant chemotherapy for Dukes'C colon cancer. The oral 5-FU prodrugs, such as UFT and capecitabine, will replace 5-FU infusion in the adjuvant chemotherapy in the near future. In Dukes'B colon cancer, the results of postoperative adjuvant chemotherapy are controversial. Many randomized trials in the USA and Europe have demonstrated that pre- or postoperative radiation therapy for rectal cancer decreases local recurrences but has no additional benefit on survival compared with 5-FU-based adjuvant chemotherapy. Adjuvant radiation therapy for rectal cancer is not widely used in Japan, while chemotherapy is considered the adjuvant treatment of choice. The local recurrences of rectal cancer is a surgeon-related phenomenon: the surgical technique used and the skill of the surgeon are major factors influencing outcome.

Original languageEnglish
Pages (from-to)2488-2497
Number of pages10
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number13
Publication statusPublished - Dec 2002

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Progress in adjuvant therapy for colorectal cancer'. Together they form a unique fingerprint.

Cite this